Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Arvinas, Inc.

35 indications, side-by-side phase, drug & LoA

$6.98

-0.25 (-3.45%)

C 40Pipeline Score Fair Value Biotech · Commercial
Market Cap
516.17 M
EPS
-3.26
P/E Ratio
-2.46 $
Value Trade
9.83 M
SEC Financials
Q1 2026

  • Dilution Risk

    15%

  • Revenue

    15.60 M

  • R&D Expenses

    60.30 M

  • Operating CF

    -69.20 M

  • Total Assets

    647.50 M

  • Total Liabilities

    260.70 M

  • Equity

    386.80 M

  • D/E Ratio

    12,345

-2.26 %
Week
-15.05 %
1 Month
-26.22 %
3 Month
-17.36 %
6 Month
-86.43 %
5 Year
-56.71 %
All Time
Cash Data
Healthy

  • Cash Position

    614.90 M

  • Monthly Burn

    23.07 M

  • Runway

    25.7 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 11, 2026
Overview
Volume
680.25 K
52 Week Range
6.06 - 14.51
% held by Insiders
15.73 %
% held by Institutions
75.86 %
Enterprise Value
-90.13 M
Total Shares
64.50 M
Short %
9.05 %
Float Shares
51.98 M
Company Description
HQ: 395 WINCHESTER AVE, NEW HAVEN,...
Founded:2013
Employees:246
https://www.arvinas.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C40
Pipeline Score
$393M
Pipeline Value
Fair Value
Valuation Signal
5
Drugs Scored
0.8x
rNPV / MCap
Top 54%
Micro Cap
(rank 417 of 905)
Percentile Rank
Arvinas, Inc. carries a moderate pipeline score (40/100), with $982M risk-adjusted pipeline value, led by ARV-471 in Breast Cancer (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
ARV-471
Small molecule		Breast CancerPhase 2NCT0407295219% $619M COMPLETED 369 FAST C (47) Mar 5, 2026MODERATE_RISKMEDIUM
May 26, 2026
Unlock Drug Pipeline Intelligence
ARVN Clinical Trial Results & History
Drug Name Indications Phase Date Trial Results Summary Title Source
ARV-393
nodal T-follicular helper cell lymphoma,angioimmunoblastic-type,transformed follicular lymphoma,diffuse large B-cell lymphoma
Phase 1
2025-06-16
ARV-393
nodal T-follicular helper cell lymphoma,angioimmunoblastic-type,transformed follicular lymphoma,diffuse large B-cell lymphoma
Phase 1
2025-06-16
ARV-393
nodal T-follicular helper cell lymphoma,angioimmunoblastic-type,transformed follicular lymphoma,diffuse large B-cell lymphoma
Phase 1
2025-06-16
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ARVN
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ARVN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ARVN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ARVN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ARVN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ARVN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Arvinas, Inc. (ARVN) News & Alerts
-
Thursday, June 11, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ARVN ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Lymphoma #42 of 69 PHASE 1 ARV-393 + Glofitamab
REGN LLY MRK
$8.52B 0.85 FOLLOWER